Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose rituximab 500 mg/m² for glucocorticoid-ineffective or glucocorticoid-dependent primary immune thrombocytopenia
ChiCTR1900027748Phase 4Recruiting
- Sponsor
- Department of Hematology, Second Affiliated Hospital of Kunming Medical University
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in immune thrombocytopenia (ITP), sponsored by Department of Hematology, Second Affiliated Hospital of Kunming Medical University. Primary endpoint: Platelet count. Started May 2020; status: recruiting.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR1900027748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027748.